Emergent Biosolutions Inc (EBS)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
EBS
Emergent Biosolutions Inc
$6.80
-3.42%
HEALTHCARE · Cap: $319.43M
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.91
-0.73%
HEALTHCARE · Cap: $60.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 599606% more annual revenue ($4.62T vs $770.20M). TAK leads profitability with a -3.5% profit margin vs -23.0%. EBS appears more attractively valued with a PEG of 0.38. EBS earns a higher WallStSmart Score of 64/100 (C+).
EBS
Buy64
out of 100
Grade: C+
TAK
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$33.92
Current Price
$6.80
$27.12 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 66.3% year-over-year
Strong operational efficiency at 28.3%
Growing faster than its price suggests
Reasonable price relative to book value
Generating 73.8B in free cash flow
Large-cap with strong market position
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
Elevated debt levels
ROE of -1.6% — below average capital efficiency
ROE of 2.4% — below average capital efficiency
Earnings declined 9.8%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : EBS
The strongest argument for EBS centers on PEG Ratio, Price/Book, Revenue Growth. Revenue growth of 66.3% demonstrates continued momentum. PEG of 0.38 suggests the stock is reasonably priced for its growth.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bear Case : EBS
The primary concerns for EBS are Altman Z-Score, Market Cap, Debt/Equity. Debt-to-equity of 1.70 is elevated, increasing financial risk.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
EBS profiles as a hypergrowth stock while TAK is a turnaround play — different risk/reward profiles.
EBS carries more volatility with a beta of 2.34 — expect wider price swings.
EBS is growing revenue faster at 66.3% — sustainability is the question.
TAK generates stronger free cash flow (73.8B), providing more financial flexibility.
Bottom Line
EBS scores higher overall (64/100 vs 53/100) and 66.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Emergent Biosolutions Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Emergent BioSolutions Inc., a life sciences company, focuses on providing preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHT). The company is headquartered in Gaithersburg, Maryland.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?